BridgeMD
New treatment option for Cancer
Official title Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors
ClinicalTrials.gov ID: NCT03257969
What this study is testing
- What it's testing
- The rise of oral anticancer drugs favors outpatient care but exposes patients to new risks compared to injectable chemotherapy at hospital: non-adherence to treatment, inappropriate management of side effects and interactions with other co-prescribed drugs. Latrogenic risk of these treatments is reinforced in older patients with frequent comorbidities, taking multiple pharmaceutical treatments for long periods and followed by several prescribers.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient aged 18 years old or more
- With cancer
- For wich the initiation or change of an oral anticancer drug is prescribed
- With life expectancy estimated to be 6 months or more, in the opinion of the investigator
- Of which the treatment with oral anticancer medication is estimated to be 6 months or more in the opinion of the oncologist
You likely can't join if
- Pregnant or lactating woman
- Patient on anti-PD1, anti-PDL-1 or anti-CTLA4-4 immunotherapy concomitant with oral anticancer treatment
- Patient under radiotherapy concomitant treatment with oral anticancer
- Oral anticancer agent prescribed in a delivery circuit as part of an ATU or clinical trial;
- Patient with significant cognitive or psychiatric disorders, in the opinion of the investigator;
- Management of drug treatment at home is performed exclusively by the caregiver;
See the full eligibility criteria
- Patient aged 18 years old or more
- With cancer
- For wich the initiation or change of an oral anticancer drug is prescribed
- With life expectancy estimated to be 6 months or more, in the opinion of the investigator
- Of which the treatment with oral anticancer medication is estimated to be 6 months or more in the opinion of the oncologist
- Benefiting from an initiation or a change of oral anticancer agents according to the MA: cytotoxic agent, targeted therapy, hormonal therapy (excluding adjuvant treatments);
- of which the oral anticancer drug is delivered in pharmacy of town or in retrocession hospital;
- With ambulatory status (not hospitalized for the management and treatment )
- Taking 5 or more drugs, including the oral anticancer treatment, and / or treated with an oral anticancer drug requiring complex regimen (combination of 2 oral anticancer drugs, or sequential rate of intake, or...
- With a sufficient autonomy for the management of medication at home
- Without either cognitive disorders or major psychiatric disorders, in the opinion of the investigator
- Ability to read, write and understand the French language
- Having given his written consent to participate in the study
- Patient affiliated to the social security scheme or equivalent
- Pregnant or lactating woman
- Patient on anti-PD1, anti-PDL-1 or anti-CTLA4-4 immunotherapy concomitant with oral anticancer treatment
- Patient under radiotherapy concomitant treatment with oral anticancer
- Oral anticancer agent prescribed in a delivery circuit as part of an ATU or clinical trial;
- Patient with significant cognitive or psychiatric disorders, in the opinion of the investigator;
- Management of drug treatment at home is performed exclusively by the caregiver;
- Not having declared a doctor;
- Not having a usual city pharmacy, or reporting 2 or more usual city pharmacies;
- Patient who has already benefited from a therapeutic education program
- In institution or guardianship, major protected by the Law.
The study team makes the final eligibility decision.
Where it's taking place
- Pierre-Bénite, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Pierre-Bénite, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.